Investment Thesis
Spruce Biosciences is a pre-revenue biopharmaceutical company burning significant cash with zero revenue generation and -$12.3M net losses. While strong liquidity ($54.1M cash) provides near-term runway, the company faces severe operational challenges with negative operating cash flow (-$8.7M) and only ~6 quarters of cash runway at current burn rates without visible revenue generation.
Strengths
- Exceptional cash position of $54.1M provides runway for clinical development and operations
- Strong liquidity ratios (4.67x current ratio) enable debt service and operational flexibility
- Net loss improved 26.5% YoY, indicating some cost management and progress toward profitability
Risks
- Complete revenue collapse (-100% YoY) with zero revenue indicates pre-commercial stage with no approved products
- Significant operating losses (-$12.0M) and negative operating cash flow (-$8.7M) unsustainable without revenue generation
- Limited cash runway of ~6 quarters at current burn rate; company dependent on financing or clinical success
- Biotech sector execution risk with no visible near-term revenue catalysts or approved product portfolio
- Minimal insider activity (1 Form 4 filing in 90 days) signals lack of insider confidence
Key Metrics to Watch
- Operating cash burn rate and cash runway extension/depletion timeline
- Clinical trial progress and FDA milestone achievements for pipeline products
- Revenue generation from approved products or licensing partnerships
Financial Metrics
Revenue
0.0
Net Income
-12.3M
EPS (Diluted)
$-8.94
Free Cash Flow
-8.7M
Total Assets
56.2M
Cash
54.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-35.4%
ROA
-21.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
4.67x
Quick Ratio
4.67x
Debt/Equity
0.59x
Debt/Assets
38.3%
Interest Coverage
-17.78x
Long-term Debt
20.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T06:57:50.921077 |
Data as of: 2026-03-31 |
Powered by Claude AI